Slide 1: Twilight Investor Briefing
For personal use only ™ Twilight Investor Briefing Gary Phillips, CEO 6th March 2024
Slide 2: Forward looking statement
Forward looking statement For personal use only This document contains involve known and unknown forward-looking statements, risks, uncertainties and other including statements factors, many of which are concerning Syntara’s future beyond our control, and which financial position, plans, and may cau
Slide 3: Global leaders in lysyl oxidase enzymes; prioritising myelofibrosis
For personal use only Global leaders in lysyl oxidase Prioritising Myelofibrosis (MF) • Market opportunities in excess of US$1b per enzymes with three Nature annum and recent history of biotech exits in publications and a pipeline of clinical excess of US$1.7b stage drugs in fibrosis and • SNT-5505
Slide 4: Shareholders & cash
Shareholders & cash Financial Information 04 mar 24 For personal use only Institutional Ownership 29 Feb 24 ASX Code SNT D&A Income Limited 20% Platinum Investment Management 20% Share price $0.023 Limited BVF Partners LP 9% Market Cap A$27m Total Institutional Ownership 60% Proforma cash balance (3
Slide 5: Pharmaxis evolves to Syntara: cost savings and clear clinical focus
Pharmaxis evolves to Syntara1: Cost savings and clear clinical focus For personal use only The main factors impacting cash from separation of the mannitol business unit are: Proforma Cash Expenses 2023 • Employee numbers dropping from ~67 to ~26 35,000 FTE’s 30,000 • Much reduced space requirement -
Slide 6: Syntara Board under new leadership and downsized
Syntara Board under new leadership and downsized Significant international pharmaceutical experience For personal use only Dr Kathleen Metters Dr Simon Green Gary Phillips Hashan De Silva Chair Non-Executive Director Chief Executive Officer Non-Executive Director • Former Senior Vice President • Exp
Slide 7: Syntara is the global leader in lysyl oxidase chemistry and biology
Syntara is the global leader in lysyl oxidase chemistry and biology Multi year research program leveraged with extensive For personal use only scientific collaborations worldwide has delivered 3 drugs now in phase 1c/2 studies Lysyl oxidases mediate the final stage in fibrosis SNT-5505 in Oncology T
Slide 8: Preclinical science and collaborations validated in high impact publications
Preclinical science and collaborations validated in high impact publications For personal use only Myelofibrosis Myelodysplastic • Treatment with Syndrome lysyl oxidase • In xenograft inhibitor mouse model that significantly closely resembles reduced reticulin human disease, fibrosis and SNT-5505 on
Slide 9: Myelofibrosis (MF)
For personal use only Myelofibrosis (MF)
Slide 10: Myelofibrosis
Myelofibrosis A rare type of bone marrow cancer that disrupts the body's normal production of blood cells For personal use only Key Facts Primary Myelofibrosis is Current standard SNT-5505 characterised by a build up of scar of care (SoC): JAK inhibition In contrast to SoC tissue (fibrosis) in bone
Slide 11: SNT-5505 Phase 2a trial (interim results)
SNT-5505 Phase 2a trial (INTERIM results) For personal use only Study status Efficacy • 100% of target (24 pts) enrolled • 5/ 10 evaluable patients* had improved bone • 11 patients having completed 24 marrow fibrosis scores of ≥1 grade weeks of treatment - 4 out of 5 fibrosis responders demonstratin
Slide 12: Phase 2a study; SNT-5505 in patients on a stable dose of JAK inhibitor
Phase 2a study; SNT-5505 in patients on a stable dose of JAK inhibitor Fastest route to meaningful data with no dose escalation and utilizing existing trial infrastructure Study Plan For personal use only • 19 clinical trial sites • Recruitment Study Treatment started 13 Dec Design Endpoints Populat
Slide 13: Myelodysplastic Syndromes (MDS)
For personal use only Myelodysplastic Syndromes (MDS)
Slide 14: Myelodysplastic syndrome (MDS) is a blood cancer
Myelodysplastic syndrome (MDS) is a blood cancer Diverse bone marrow disorders characterized by inadequate production of healthy blood cells Key Facts 12–20k new cases are reported every Treatment of MDS For personal use only year in the US (87k p.a. worldwide) Current standard of care Drugs in deve
Slide 15: Phase 1c/2a study; SNT-5505 in MDS patients
Phase 1c/2a study; SNT-5505 in MDS patients Study organisation Fastest route to meaningful data with no dose escalation and utilizing existing trial infrastructure For personal use only • $0.83m grant from the Australian Medical Research Future Study Treatment Fund (MRFF). Patients Design Endpoints
Slide 16: Skin Scarring
For personal use only Skin Scarring
Slide 17: Hypertrophic and keloid scarring
Hypertrophic and keloid scarring Cutaneous scarring following skin trauma or a wound is a major cause of morbidity and disfigurement For personal use only Key Facts • Mechanisms underlying scar • Pre clinical evidence formation are not well established; prophylactic and - Treatment with SNT-6302 100
Slide 18: SNT-6302 phase 1c trial in established skin scars (Solaria); top line results
SNT-6302 phase 1c Trial in established skin scars (Solaria 2); Top line results For personal use only SNT-6302 well tolerated Mean inhibition of LOX Meaningful changes in the Longer study required to and demonstrated a activity 66% compared to composition of the scars show appearance and good safety
Slide 19: Potential to deliver near term value
Potential to deliver near term value Pipeline creates multiple opportunities in high value markets Drug Upcoming Addressable For personal use only Indication Phase Trial design Status Candidate Milestones market (US$) • Open label 12 month study (n=15) First H2 2024: Myelofibrosis (MF) Phase 2 • MF
Slide 20: News flow
News flow Recent and anticipated news flow Strong and growing pipeline with advancement in For personal use only studies expected to provide value inflection points Q4 2023 H1 2024 H2 2024 • SNT-5505 phase 2a myelofibrosis • Pan-LOX scar prevention for burn • SNT-5505 phase 1c/2a combination study (
Slide 21: Contact details
For personal use only Gary Phillips Syntara Limited ABN 75 082 811 630 Chief Executive Officer gary.phillips@syntaraTX.com.au David McGarvey Chief Financial Officer david.mcgarvey@syntaraTX.com.au www.syntaraTX.com.au